Clinical Trials on PD1

Total 265 results

Forest Laboratories

Terminated

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Estonia, Hungary, Iceland, Italy, Korea, Republic of, Serbia, Ukraine, Canada, Colombia, Belgium, France, New Zealand, Poland, South Africa, Spain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaborators

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-003)

Radiotherapy | HNSCC | PD-1

China
Rockwell Medical Technologies, Inc.

Completed

Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis

Anemia | Chronic Kidney Disease | Peritoneal Dialysis (PD)
University Hospital Heidelberg
Department of Dermatology, Heidelberg University Hospital

Completed

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Sportivumab)

Melanoma | Exercise | PD-1 Antibodies

Germany
Guangdong Provincial People's Hospital

Unknown

Standardization and Optimization of TMS Protocols for the Treatment of PD With Depression or Cognitive Impairment

TMS Protocols in the Treatment of PD

China
Sarah Goldberg
Mirati Therapeutics Inc.

Terminated

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | Sitravatinib

United States
Men's Health Boston

Completed

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

Peyronie's Disease (PD)

United States
Medical College of Wisconsin

Terminated

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants (Fenaki)

Acute Kidney Injury (AKI) | Patent Ductus Arteriosus (PDA)

United States
Assiut University

Not yet recruiting

Evaluation of Sun's Scoring System Use in Post-pancraticodoudenectomy Pancreatic Fistula

Risk Scoring System for Prediction of Pancreatic Fistula Post PD
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
Fudan University

Not yet recruiting

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Gastric Cancer | MSI-H | Adjuvant Therapy | PD-1 Immunotherapy

China
Ocuphire Pharma, Inc.

Completed

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy (ZETA-1)

Diabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic Retinopathy

United States
Chinese PLA General Hospital

Not yet recruiting

Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma
Boston Scientific Corporation

Recruiting

Coordinated Reset Deep Brain Stimulation (RESET-DBS)

Parkinson's Disease (PD)

Germany
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Parkinson's Disease (PD)

Netherlands
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Consorzio Oncotech

Active, not recruiting

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Metastatic Breast Cancer | Triple Negative Breast Cancer | PD-L1 Gene Mutation

Italy
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

China
Peking University Cancer Hospital & Institute

Recruiting

PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor

Melanoma | Lung Cancer | PD-L1 | PET/CT

China
Alnylam Pharmaceuticals

Completed

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

Primary Hyperoxaluria | PH1 | RNAi Therapeutic | siRNA | AGT

France, United Kingdom, Netherlands, Israel, Germany
Kidney Cancer Research Bureau

Recruiting

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NIVOFGFR2)

Metastatic Gastric Cancer | FGFR2 Amplification | PD-L1 Gene Amplification

United States
RenJi Hospital

Recruiting

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Urothelial Carcinoma Bladder | PD-1 Inhibitor

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Alnylam Pharmaceuticals

Completed

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 (ILLUMINATE-A)

Primary Hyperoxaluria Type 1 (PH1)

United States, France, United Kingdom, Switzerland, Netherlands, Israel, Germany, United Arab Emirates
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Available

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

Primary Hyperoxaluria Type 1 (PH1)
Sun Yat-sen University

Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion Chemotherapy

China
Altec Inc.
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

A Smartphone Application for Neurology and Telemedicine (NeuroVision)

Parkinson Disease(PD)

United States
Beijing Tiantan Hospital

Recruiting

EC50 of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients With Parkinson's Disease

PD - Parkinson's Disease

China
AbbVie

Active, not recruiting

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia
AbbVie

Completed

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia
Shirish M Gadgeel
AstraZeneca; Henry Ford Health System

Withdrawn

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Lung Cancer | Non-small Cell Lung Cancer | PD-L1 Gene Mutation | KRAS Activating Mutation

United States
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
Shanghai Cancer Hospital, China

Unknown

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT

China
Bial - Portela C S.A.

Completed

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide

Parkinson's Disease (PD)

Canada
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Australia, Korea, Republic of
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Anlotinib | Anti-PD-1 Antibody | Advanced Pancreatic Cancer

China
Baylor College of Medicine

Completed

MER Versus MRI Guidance DBS in Parkinson's Disease

Idiopathic Parkinson's Disease (PD)

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University; Shenzhen University General...

Recruiting

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 Inhibitor

China
Lei Li

Recruiting

Genetic Mutation in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1

China
Peking University Third Hospital

Completed

Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer

Pancreatic Cancer | Stereotactic Body Radiotherapy | PD-1 Inhibitors

China
Icahn School of Medicine at Mount Sinai

Terminated

Cognitive Protection - Dexmedetomidine and Cognitive Reserve

Postoperative Delirium | Postoperative Cognitive Dysfunction | PD | POCD

United States
Dicerna Pharmaceuticals, Inc.

Completed

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 (PHYOX2)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2)

Poland, United Kingdom, New Zealand, United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Lebanon, Netherlands, Romania, Spain
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

France

Clinical Trials on PD1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations